Sutro Biopharma GAAP EPS of -$22.49 misses by $7.28, revenue of $102.48M beats by $3.3M
Source: SeekingAlpha
2026-03-23 16:14:00 ET
More on Sutro Biopharma
- Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026
- Sutro Biopharma, Inc. (STRO) Presents at 16th Annual World ADC London Summit - Slideshow
- Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Sutro Biopharma prices $110M common stock offering
- Seeking Alpha’s Quant Rating on Sutro Biopharma
Read the full article on Seeking Alpha
For further details see:
Sutro Biopharma GAAP EPS of -$22.49 misses by $7.28, revenue of $102.48M beats by $3.3M
Sutro Biopharma Inc.
NASDAQ: STRO
STRO Trading
1.58% G/L:
$40.20 Last:
70,864 Volume:
$43.85 Open:
STRO Latest News
May 14, 2026 04:05:00 pm
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsApril 19, 2026 07:45:00 pm
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026March 23, 2026 04:05:00 pm
Sutro Biopharma Reports Full Year 2025 Financial Results and Business HighlightsSTRO Stock Data
$132,896,188
8,207,042
0.54%
38
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
